MX2009009636A - Metodos para tratar enfermedades oftalmicas. - Google Patents

Metodos para tratar enfermedades oftalmicas.

Info

Publication number
MX2009009636A
MX2009009636A MX2009009636A MX2009009636A MX2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A
Authority
MX
Mexico
Prior art keywords
methods
ophthalmic diseases
treating ophthalmic
treating
inhibitors
Prior art date
Application number
MX2009009636A
Other languages
English (en)
Inventor
Chia-Yang Lin
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of MX2009009636A publication Critical patent/MX2009009636A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen métodos para usar inhibidores (incluyendo anticuerpos monoclonales) dirigidos contra el péptido amiloide-beta para el tratamiento de enfermedades oftálmicas tales como degeneración macular relacionada con la edad.
MX2009009636A 2007-03-09 2008-03-06 Metodos para tratar enfermedades oftalmicas. MX2009009636A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89418107P 2007-03-09 2007-03-09
US12/041,581 US20090022728A1 (en) 2007-03-09 2008-03-03 Methods of treating ophthalmic diseases
PCT/IB2008/000486 WO2008110885A2 (en) 2007-03-09 2008-03-06 Methods of treating ophthalmic diseases

Publications (1)

Publication Number Publication Date
MX2009009636A true MX2009009636A (es) 2009-12-11

Family

ID=39760152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009636A MX2009009636A (es) 2007-03-09 2008-03-06 Metodos para tratar enfermedades oftalmicas.

Country Status (15)

Country Link
US (1) US20090022728A1 (es)
EP (1) EP2134751A2 (es)
JP (2) JP5964004B2 (es)
KR (2) KR101259225B1 (es)
CN (2) CN101687922B (es)
AU (1) AU2008224600B2 (es)
BR (1) BRPI0808711A2 (es)
CA (1) CA2680222C (es)
HK (1) HK1201046A1 (es)
IL (1) IL200528A0 (es)
MX (1) MX2009009636A (es)
NZ (1) NZ579273A (es)
RU (1) RU2434639C2 (es)
TW (1) TWI449535B (es)
WO (1) WO2008110885A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
SG2014013437A (en) 2005-11-30 2014-07-30 Abbott Lab Monoclonal antibodies and uses thereof
MX2009000476A (es) 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2015200604B2 (en) * 2007-10-05 2016-10-27 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
CA2701790A1 (en) * 2007-10-05 2009-04-16 Ac Immune S.A. Use of humanized anti-beta-amyloid antibody in ocular diseases
US20110014182A1 (en) 2007-12-11 2011-01-20 Philippe Marc Louis Alard Antigen binding proteins
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2014511174A (ja) 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Ａｐｏｅ免疫療法
RU169012U1 (ru) * 2016-08-08 2017-03-01 Дмитрий Викторович Давыдов Электрод для электростимуляции зрительного нерва и зрительных путей и контроля физиологических параметров орбитальных структур глаза
WO2018200620A1 (en) * 2017-04-25 2018-11-01 National Cheng Kung University Use of il-20 antagonists for treating eye diseases
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025516A2 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006039327A2 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
AU2006211625A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
MX2008007477A (es) * 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
MX2009000476A (es) * 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
PL2074145T3 (pl) * 2006-10-02 2017-11-30 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta

Also Published As

Publication number Publication date
KR20090119990A (ko) 2009-11-23
CN101687922B (zh) 2014-06-11
CN101687922A (zh) 2010-03-31
TWI449535B (zh) 2014-08-21
RU2009133789A (ru) 2011-03-20
AU2008224600B2 (en) 2011-09-29
JP5964004B2 (ja) 2016-08-03
BRPI0808711A2 (pt) 2014-08-12
RU2434639C2 (ru) 2011-11-27
CA2680222C (en) 2013-10-08
IL200528A0 (en) 2010-04-29
HK1201046A1 (en) 2015-08-21
KR20120054105A (ko) 2012-05-29
TW200900079A (en) 2009-01-01
WO2008110885A3 (en) 2009-01-15
AU2008224600A1 (en) 2008-09-18
CN104027803A (zh) 2014-09-10
CA2680222A1 (en) 2008-09-18
WO2008110885A2 (en) 2008-09-18
KR101259225B1 (ko) 2013-04-30
NZ579273A (en) 2012-03-30
JP2015038109A (ja) 2015-02-26
EP2134751A2 (en) 2009-12-23
JP2009062358A (ja) 2009-03-26
US20090022728A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MY156662A (en) Amine derivative compounds for treating ophthalmic diseases and disorders
EP2582722A4 (en) ANTIBODIES AGAINST GD2
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
NZ706377A (en) Il-6 antagonists and uses thereof
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
PH12015502017A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease
SG171690A1 (en) Treatment of protein degradation disorders
MY149630A (en) Antibodies against amyloid-beta peptide
EA200971077A1 (ru) Гетероциклические модуляторы киназы
TN2012000555A1 (en) Antibodies to human gdf8
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX350355B (es) Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration